Netupitant

Drug Profile

Netupitant

Alternative Names: R 1124; Ro 67-3189/000

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Helsinn; Taiho Pharmaceutical
  • Class Antiemetics; Pyridines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced nausea and vomiting; Pruritus
  • Discontinued Overactive bladder

Most Recent Events

  • 31 Aug 2017 Phase-II clinical trials in Chemotherapy induced nausea and vomiting (Prevention, In adolescents, In children, In infants, In neonates, Combination therapy) in USA (PO) (NCT03204279)
  • 04 Jul 2017 Helsinn plans a phase II trial for Chemotherapy induced nausea and vomiting (Prevention, In adolescents, In children, In infants, In neonates, Combination therapy) in USA, Russia, Serbia and Ukraine (NCT03204279)
  • 12 Oct 2015 Phase-II clinical trials in Chemotherapy induced nausea and vomiting (Prevention) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top